Scarica l'app Stockscreener
61.03
3.00%
-1.89
Dopo l'orario di chiusura:
60.68
-0.35
-0.57%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Arrowhead Pharmaceuticals Inc (HDP1.HM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Arrowhead Pharmaceuticals, Inc. (A2RR34.SA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tema Etfs LLC Reduces Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. (HDP1.F) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Arrowhead Pharmaceuticals Leads with 415.53% Return in Stock Performance - Markets Mojo
ARWR Stock Price, Quote & Chart | ARROWHEAD PHARMACEUTICALS IN (NASDAQ:ARWR) - ChartMill
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Arrowhead (ARWR) FQ1 2026 revenue hits $264M as REDEMPLO approval marks commercial shift - MSN
Arrowhead Pharmaceuticals, Inc. (ARWR) Jumps 7.3% to $61.87 - AlphaStreet
Q4 2025 Arrowhead Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo - marketscreener.com
Arrowhead Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Arrowhead Plozasiran Data Supports Triglyceride Reduction And Valuation Upside Potential - Yahoo Finance
Arrowhead Pharmaceuticals (ARWR) price target increased by 17.24% to 59.24 - MSN
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Sp - pharmiweb.com
Trading Systems Reacting to (ARWR) Volatility - Stock Traders Daily
Arrowhead Pharmaceuticals Inc (LTS:0HI3) Bonds - GuruFocus
BofA Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Cuts Target Price to $81 - moomoo.com
Stock List: Research Stocks from Around the World - GuruFocus
Vanguard amendment shows 0% holding in Arrowhead (ARWR) - Stock Titan
Arrowhead Pharma stock rating reiterated at Buy by TD Cowen - Investing.com South Africa
Analysts Conflicted on These Healthcare Names: Cibus (CBUS), Arrowhead Pharmaceuticals (ARWR) and Tarsus Pharmaceuticals (TARS) - The Globe and Mail
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap DownWhat's Next? - MarketBeat
BofA cuts Arrowhead Pharma stock price target on obesity prospects By Investing.com - Investing.com India
BofA cuts Arrowhead Pharma stock price target on obesity prospects - Investing.com
Sarepta Pushes Past Gene Therapy Debacle as RNA Therapies Show Early Promise - BioSpace
Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead (NASDAQ:ARWR) - seekingalpha.com
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Strong One Year Shareholder Return - Sahm
Leerink reiterates Arrowhead Pharma stock rating on partner data By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals Surges as Clinical Trial Doses First Patients - StocksToTrade
Arrowhead Pharma (ARWR) Rating Reiterated as 'Buy' by HC Wainwri - gurufocus.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives "Buy" Rating from HC Wainwright - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 8.6%Here's What Happened - MarketBeat
Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets - Barron's
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Nordea Investment Management AB - MarketBeat
Assenagon Asset Management S.A. Purchases 304,264 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
JPMorgan Chase & Co. Grows Stake in Arrowhead Pharmaceuticals, Inc. $ARWR - marketbeat.com
Exit Recap: Whats the beta of Arrowhead Pharmaceuticals Inc stockWeekly Gains Summary & High Yield Equity Trading Tips - baoquankhu1.vn
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Hudson Bay Capital Management LP - MarketBeat
Arrowhead Shareholders Reject Say-on-Pay at 2026 Meeting - The Globe and Mail
B of A Securities Maintains Arrowhead Pharmaceuticals (ARWR) Buy Recommendation - MSN
Arrowhead Pharmaceuticals (NASDAQ: ARWR) holders back board but reject Say-on-Pay - stocktitan.net
Arrowhead Advances Zodasiran Into Phase 3 HoFH Study, Signaling Long-Term Growth Potential - TipRanks
A Look At Arrowhead Pharmaceuticals (ARWR) Valuation As Recent Momentum Cools After A Strong Run - Yahoo Finance
Arrowhead’s bid to become a large-cap biotech - BioCentury
Arrowhead Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo Finance
Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma - Insider Monkey
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
Arrowhead Pharmaceuticals (ARWR) Is Down 5.4%What's Changed - simplywall.st
Arrowhead Pharmaceuticals earns $100M milestone from Sarepta Therapeutics - MSN
How Arrowhead Pharmaceuticals Inc. (ARWR) Affects Rotational Strategy Timing - Stock Traders Daily
Fred Alger Management LLC Acquires New Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Bought by Boothbay Fund Management LLC - MarketBeat
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):